Login to Your Account

FDA's Graham Fires More Cardio Risk Bullets at Avandia

By Donna Young

Wednesday, June 30, 2010
WASHINGTON – FDA epidemiologist David Graham has insisted for years that regulators should remove from the U.S. market GlaxoSmithKline plc's Type II diabetes drug Avandia (rosiglitazone), and a new study demonstrating the medicine is tied to an increased risk of stroke, heart failure and death has given him more ammunition to wage that battle. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription